CV Sciences, Inc. Set to Release Second‑Quarter 2026 Financial Results
On August 10, 2026, CV Sciences, Inc. (OTCQB:CVSI) announced that it will disclose its financial performance for the quarter ended June 30, 2026 after the market close on Thursday, August 13, 2026. The consumer‑wellness firm, known for its hemp‑extract and plant‑based product lines, will follow the release with a live conference call at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day.
Details of the Investor Call and Webcast
Investors and analysts can access the live webcast through the Investor Relations section of the company’s website at https://ir.cvsciences.com/news-events or directly via the streaming link https://viavid.webcasts.com/starthere.jsp?ei=1769578&tp_key=ae0ce79bc9. The presentation will remain archived for approximately 30 days.
For those preferring a telephone connection, the dial‑in numbers are (877) 407‑0784 for U.S. callers and (201) 689‑8560 for international participants. The company recommends joining the call about 15 minutes before the scheduled start to accommodate high call volumes.
A replay of the call will be available roughly two hours after its conclusion and can be accessed through Thursday, August 20, 2026 by dialing (844) 512‑2921 (U.S.) or (412) 317‑6671 (international) and entering confirmation code 13761707.
About CV Sciences, Inc.
CV Sciences positions itself as a leader in the consumer wellness space, focusing on nutraceuticals, plant‑based foods, and hemp‑derived ingredients. The firm’s flagship +PlusCBD™ line is sold through both B2B and B2C channels and has been recognized by SPINS—the leading provider of syndicated data for the natural, organic, and specialty products market—as the top‑selling hemp‑extract brand in the natural products sector.
The company backs its product claims with scientific rigor. Human clinical research data support the benefits of +PlusCBD™ in healthy individuals, and three published clinical case studies are available on PubMed.gov. Notably, +PlusCBD™ was the first hemp‑extract supplement brand to pursue self‑affirmed Generally Recognized as Safe (GRAS) status, a move that underscores its commitment to safety and regulatory compliance.
Beyond cannabinoids, CV Sciences markets non‑cannabinoid supplements under the +PlusHLTH™ brand, targeting formulations that aim to enhance health, performance, and vitality. Its Cultured Foods™ portfolio offers 100 % plant‑based food items, primarily distributed in the EU and select other markets, catering to vegan, gluten‑free, and flexitarian consumers. Additionally, the company owns Elevated Softgels, a manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industries.
CV Sciences maintains operational hubs in San Diego, California; Grand Junction, Colorado; and Warsaw, Poland. Further information about the firm can be found on OTCMarkets.com or by visiting www.cvsciences.com.
Forward‑Looking Statements
The press release contains forward‑looking statements as defined under Sections 27A and 21E of the Securities Act of 1933 and the Securities Exchange Act of 1934. These statements reflect the company’s expectations regarding future events and financial outcomes but are subject to risks and uncertainties. CV Sciences does not undertake an obligation to update such statements except as required by law, and readers are cautioned not to place undue reliance on them.
Contact Information
For investor relations inquiries, please email ir@cvsciences.com.
Source: Here
